

## Decompensated Liver Disease in the Hospitalized Patient

Janice Jou, MD MHS
Associate Professor of Medicine
Division of Gastroenterology
NW Regional Hospital Medicine Conference

### Outline

- Definitions
  - Acute Liver Failure (ALF)
  - Acute on Chronic Liver Failure (ACLF)
- Prognostication in ACLF
- EtOH hepatitis
  - Liver Transplantation



### Case

- 42yo female with a diagnosis of EtOH hepatitis and cirrhosis 3 months prior to presentation, now admitted for worsening ascites. She is awake but has slow speech
- Exam: Jaundiced, distended abd but not tense, +asterixis
- Tbili 13.5 (stable), Alk phos 127, AST 119, ALT 64
- INR 2.9 (Baseline 1.8 ~1 week ago)
- Cr 2.1 (Baseline 1.1 ~ 1 week ago)
- Alb 2.7
- Hgb stable
- Outpatient medications:
  - Furosemide 40mg, Spironolactone 100mg
  - Lactulose 2 tsp BID




### **Acute Liver Failure**

#### General Definition:

- No pre-existing liver disease
- Acute hepatocellular damage
- Coagulopathy
- Encephalopathy

- <u>Uncommon</u> entity
  - 1 case per million people
- If a patient doesn't have encephalopathy, then it's not ALF!
  - Severe acute liver injury only
- Decompensated chronic liver disease that can present as fulminant disease
  - Wilson
  - Autoimmune hepatitis
  - HBV







## Acute-on-chronic liver failure (ACLF)- What is it?

- "I know it when I see it!"
- "The entity is not new. All physicians who have followed hospitalized patients with cirrhosis have been seeing this type of patient over their entire career....ACLF has taken on a life of its own and has led to a vast body of literature...However, it has also led to confusion because ACLF is considered by many as a new diagnostic entity rather than, what it really is, an old entity of prognostic significance that is still in search of a unifying definition."
  - Guadalupe Garcia-Tsao



## **ACLF-** general definition

- Very common entity
- No consensus definition
- Decompensation of liver disease in a patient with <u>underlying</u> <u>chronic liver disease/cirrhosis with extrahepatic organ</u> <u>failures</u>
  - Liver failure- coagulopathy, encephalopathy
- Extrahepatic Organ failures:
  - Kidney
  - Cerebral (hepatic encephalopathy)
  - Circulation
  - Pulmonary
- Thought to secondary to proinflammatory state with increased cytokine production leading to multiorgan failure






Fig. 1. Cumulative transplant-free survival curves of patients from the CANONIC study. Kaplan-Meier 90-day transplant-free cumulative survival curves of patients from the CANONIC study7 with or without ACLF (traditional AD). Kaplan-Meier Curves were compared using the log-rank test. ACLF, acute-on-chronic liver failure; AD, acute decompensation.




## **Grading ACLF**


- Most accepted grading system
  - European CANONIC study definition (Moreau et al.)
    - ACLF 1
      - (i) single kidney failure (sCr≥2.0), (ii) single failure of the liver, coagulation, circulation, or respiration who had a sCr 1.5 to 1.9 mg/dl, and (iii) single cerebral failure who had a sCr 1.5 to 1.9 mg/dl.
    - ACLF Grade 2- 2 organ failures
    - ACLF Grade 3- 3 organ failures
- North American Consortium for the Study of End-Stage Liver Disease (NACSELD)
  - 2 of 4 organ failures as kidney, brain, circulatory, and respiratory failures



Failing organ	European Association for the Study of Liver-Chronic Liver failure organ failures definition (9)				
Liver	Bilirubin level of >12 mg/dL				
Kidney	Creatinine level of ≥2.0 mg/dL or renal replacement				
Brain	West-Haven hepatic encephalopathy grade 3–4				
Coagulation	INR ≥2.5				
Circulation	Use of vasopressor (terlipressin and/or catecholamines)				
Respiration	$PaO_2/FiO_2$ of $\leq 200$ or $SpO_2/FiO_2$ of $\leq 214$ or need for mechanical ventilation				







Lungs

Arterial pressure (mmHg), median (p25-p75)

918 (1.72)


93.17 (84.33-102.33)

3,227 (16.91)


X

**OHSU** 

87.17 (76.83-98.50)



**OHSU** 



**OHSU** 




Fig. 1. Mortality rate\* at 28 and 90 days in patients with and without ACLF and by grade. To examine the difference between ACLF and ACLF grades, the






Fig. 1. Mortality rate\* at 28 and 90 days in patients with and without ACLF and by grade. To examine the difference between ACLF and ACLF grades, the







Fig. 1. Mortality rate\* at 28 and 90 days in patients with and without ACLF and by grade. To examine the difference between ACLF and ACLF grades, the







# Acute Kidney Injury and Hepatorenal Syndrome Definitions in cirrhosis

- Acute Kidney Injury
  - Stage 1Increase in sCr ≥
     0.3 mg/dL in 48 hours,
     or ≥50% increase in sCr
     over baseline over 7
     days
  - Stage 2- sCr 2-3xbaseline
  - Stage 3- sCr >3xbaseline
- Resolution of AKI sCr within 0.3mg/dL of baseline

- Hepatorenal syndrome
  - Cirrhosis AND ascites
  - Meets AKI criteria
  - Absence of shock
  - No nephrotoxic drugs
  - No macroscopic signs of structural kidney injury



#### All-cause mortality

			Hazard Ratio	Hazard Ratio
Study or Subgroup	log[Hazard Ratio]	SE	IV, Fixed, 95% CI	IV, Fixed, 95% CI
1.1.1 Network meta-analysis (	fixed-effect model)			
Alb_Mid_Oct_Pen vs Alb_Ter	-0.6218	0.907653	0.54 [0.09, 3.18]	+ + -
Albiys Alb_Ter	-0.163	0.108584	0.85 [0.69, 1.05]	+
Alb_Norvs Alb_Ter	0.3686	0.127321	1.45 [1.13, 1.86]	+
Alb_Octivs Alb_Ter	0.3774	0.572372	1.46 [0.48, 4.48]	<del>-                                     </del>
Alb_Mid_Oct vs Alb _Ter	0.4062	0.354005	1.50 [0.75, 3.00]	++
1.1.2 Network meta-analysis (	random-effects mo	del)		
Alb_Mid_Oct_Pen vs Alb_Ter	-0.6901	1.095408	0.50 [0.06, 4.29]	
Alb vs Alb_Ter	0.06148	0.246633	1.06 [0.66, 1.72]	<del>- -</del>
Alb_Not vs Alb_Ter	0.2852	0.213163	1.33 [0.88, 2.02]	++-
Alb_Mid_Oct vs Alb _Ter	0.3508	0.50852	1.42 [0.52, 3.85]	<del></del>
Alb_Octivs Alb_Ter	0.3753	0.746684	1.46 [0.34, 6.29]	
				0.1 0.2 0.5 1 2 5 10
				Favours intervention Favours Alb_Ter

#### Recovery from hepatorenal syndrome

Study or Subgroup	og[Hazard Ratio]	SE	Hazard Ratio IV, Fixed, 95% CI	Hazard Ratio IV, Fixed, 95% CI	
1.2.1 Network meta-analysis (fix					_
Alb vs Alb_Ter	-1.219	0.234439	0.30 [0.19, 0.47]	+	
Alb_Mid_Oct vs Alb _Ter	-1.336	0.457372	0.26 [0.11, 0.64]	<del></del>	
Alb_Mid_Oct_Pen vs Alb_Ter	-1.346	1.897449	0.26 [0.01, 10.73]	<del> </del>	
Alb_Norvs Alb_Ter	-0.1728	0.134457	0.84 [0.65, 1.09]	+	
Alb_Octvs Alb_Ter	-1.338	0.625663	0.26 [0.08, 0.89]		
1.2.2 Network meta-analysis (ra	ndom-effects mo	del)			
Alb vs Alb_Ter	-1.283	0.349056	0.28 [0.14, 0.55]	<del></del>	
Alb_Mid_Oct vs Alb _Ter	-1.356	0.596301	0.26 [0.08, 0.83]	<del></del>	
Alb_Mid_Oct_Pen vs Alb_Ter	-1.392	2.004337	0.25 [0.00, 12.63]	<del> </del>	
Alb_Norvs Alb_Ter	-0.1632	0.204158	0.85 [0.57, 1.27]	+	
Alb_Octvs Alb_Ter	-1.332	0.785026	0.26 [0.06, 1.23]	<del>- + -</del>	



Favours intervention Favours Alb\_Ter

## **CLIF ACLF calculator**

- <a href="http://www.efclif.com/scientific-activity/score-calculators/clif-c-aclf">http://www.efclif.com/scientific-activity/score-calculators/clif-c-aclf</a>
- Google: CLIF ACLF calculator





ACCEPT


## Management of ACLF

- Best conservative care
  - Difficult entity to study
  - Quality of data are not adequate to draw conclusions
- Treat infection, support GI bleed
- Aggressively treat renal failure
  - Albumin 1mg/kg up to 100g IV daily x 2 days, then 50g thereafter
  - If HRS, Midodrine and octreotide
    - IV octreotide vs. subcut (usually stop if not effective after 2 weeks)
    - Midodrine 15mg po TID- can be continued as outpatient
  - Norepinephrine can be used to increase renal perfusion
  - Terlipressin not available in the US



## **ACLF** and Liver Transplantation

#### Timing for LT in ACLF



- Patients can be too sick for LT evaluation or if listed then become too sick for LT
- If renal failure ONLY, consider liver transplant evaluation
- Typically, only ACLF 1 patients can be transplanted
  - Can patients survive the operation?



### Back to our case...

- 42yo female with a diagnosis of EtOH hepatitis and cirrhosis 3 months prior to presentation, now admitted for worsening ascites. She is awake but has slow speech
- Exam: Jaundiced, distended abd but not tense, +asterixis
- Tbili 13.5 (stable), Alk phos 127, AST 119, ALT 64
- INR 2.9 (Baseline 1.8 ~1 week ago)
- Cr 2.1 (Baseline 1.1 ~ 1 week ago)
- Alb 2.7
- Hgb stable
- Outpatient medications:
  - Furosemide 40mg, Spironolactone 100mg
  - Lactulose 2 tsp BID




## Case: ACLF

- Reportedly abstinent x 3 months
- Current decompensation could be either due progression of disease vs. precipitant
- Plan:
  - R/O infection (diagnostic tap, blood cultures, UA, CXR)
  - Check ETG/PeTH
  - U/S with dopplers (due to AKI can't get contrasted imaging)
  - Hold diuretics
  - Albumin IV 100g x 2 days
- Grade 3 ACLF
  - 56% mortality at 1 month, 75% at 3 months
  - Kidney, Cerebral (Grade 1 encephalopathy), Coagulation
  - Better short term mortality prediction than MELD



#### Distribution of adults waiting for liver transplant by diagnosis

#### OPTN/SRTR 2017 Annual Data Report: Liver





## **ACLF: EtOH Hepatitis**


- EtOH hepatitis is a classic ACLF entity
- Corticosteroids?
  - Multiple meta-analyses including a Cochrane review without any significant short or long term mortality benefit
  - If any contraindication, most would not use steroids
  - If discriminant function >32, most are still using steroids if no contraindications with low threshold to stop
  - Lille score at 7 days and stop if Lille score is >0.45
  - Steroids+NAC or NAC alone
    - No high quality data



## Liver transplantation for acute alcoholic hepatitis

- Landmark NEJM article 2011
- N=26 patients transplanted in 7 centers (mostly French)
- Severe alcoholic hepatitis at high risk of death (median Lille score, 0.88) were selected and placed on the list for a liver transplant
- Fewer than 2% of patients admitted for an episode of severe alcoholic hepatitis were selected
- Protective factors: all patients transplanted had supportive family members, no severe coexisting conditions, and a commitment to alcohol abstinence.
- 5 returned to drinking, but all >720 days after LT







## LT for EtOH hepatitis: Areas of uncertainty

- What are the long term outcomes?
- Selection criteria in the study different from our real life practice?
- Are these patients overly advantaged?
  - EtOH hepatitis patients often have labs that over estimate their global degree of clinical instability
  - Particularly in those with minimal to no kidney failure



# Is my patient with EtOH Liver Disease a liver transplant candidate?

- Patients who we previously did not consider LT candidates who <u>MAY</u> be candidates
  - Every center has their own criteria for considering evaluation for liver transplantation
- Acute EtOH hepatitis related liver failure
  - No sobriety by definition
  - No cirrhosis
  - Must be first episode of EtOH related decompensation
- Acute on chronic EtOH liver disease/cirrhosis with abstinence with at least 2 months of sobriety OUT OF THE HOSPITAL



## Case: ACLF, precipitated by EtOH

- Grade 3 ACLF 56% mortality at 1 month, 75% at 3 months
  - Kidney, Cerebral (Grade 1 encephalopathy),
     Coagulation
- MELD 40
- Liver Transplant evaluation
  - Does not guarantee listing for transplant
- Palliative Care Consult
  - Stay tuned for Dr. Arnab Mitra tomorrow!



## Summary

- Acute liver failure
  - Uncommon, and overall survival especially with acetaminophen is surprisingly favorable
- Acute on Chronic liver failure
  - Defining the syndrome is helpful for prognostication
  - Decompensated liver disease with chronic liver disease/cirrhosis WITH extrahepatic organ failure
  - ¼ hospitalized decompensated cirrhotics
  - With 2 organ failures, 30% 28 day, 50% survival at 90 days
    - For example: Kidney and cerebral



## Summary

- Liver transplantation is an option for patients with ACLF with 2 or less organ failures
- EtOH hepatitis is an emerging indication for liver transplantation
  - Highly selected patient population
- Consider Palliative Care consult for patients who have ACLF and are not LT candidates



